Following the success of C9orf72-targeting ASOs in pre-clinical models, a phase I clinical trial of the first ASO (BIIB078) targeting C9orf72 mRNA in C9orf72 ALS patients was initiated in September 2018 and is ongoing (NCT03626012). Here, C9orf72 is linked to amyotrophic lateral sclerosis.